Thin GingivaNCT05055765
Comparative Evaluation of Microneedling and Injectable Platelet Rich Fibrin in Thin Periodontal Phenotype
A study testing Microneedling and injectable- platelet rich fibrin in people with Thin Gingiva, run by Postgraduate Institute of Dental Sciences Rohtak at 1 site in India.
Trial summary
Evaluation of microneedling vs injectable -platelet rich fibrin on gingival phenotype in thin periodontal phenotype. Read more about this study
- Who is it for?
- Ages 18 to 40 yearsHealthy volunteers can take part
- Conditions the study is for
- Thin Gingiva
- What is being tested?
- Microneedling and injectable- platelet rich fibrin
- Type of treatment
- Injection or infusion, Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 20 participants
- Where
- 1 siteIndia
- Study dates
- Nov 2021to Sep 2022
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 40 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- GT of the mandibular and maxillary anterior teeth < 1 mm, gingival index (GI) of < 1
- Age 18-40 years and otherwise systemically healthy
- Patients who had completed etiological periodontal therapy with Plaque index <1, gingival index <1 and showing adequate compliance and willing to participate in the study.
Who cannot join
- Patients having systemic diseases such as hypertension, diabetes, hyperthyroidism or on medications that influence the outcome of periodontal procedure
- Pregnant and lactating women
- Smokers, tobacco users
- Previous periodontal surgery
- No haematological disorders
- Use of blood thinners
- Use of any drugs that might lead to gingival enlargement
- Stress, bruxism.
Trial locations and contacts
1 site in 1 country.
NISHI TANWAR contact
About this study
Official title: Comparative Evaluation Of Microneedling vs Injectable Platelet Rich Fibrin In Thin Periodontal Phenotype: A Randomised Split Mouth Clinical Trial
Evaluation of microneedling vs injectable -platelet rich fibrin on gingival phenotype in thin periodontal phenotype.
Read the detailed description
INTRODUCTION The gingival phenotype and different parts of the masticatory mucosa have become the subject of considerable interest in Periodontics, especially from an aesthetic and therapeutic perspective. The periodontal phenotype has been defined as the combination of gingival phenotype and buccal bone plate thickness (bone morphotype). Gingival phenotype refers to gingival thickness (GT) and keratinized tissue width (KTW).
Gingival phenotypes can be classified as scalloped and thin or flat and thick gingiva. A gingival thickness of ≥1 mm is defined as thick phenotype and a gingival thickness of ≤1 mm as thin phenotype1. Thin gingival phenotype are very friable and might be prone to recede in response to traumatic insults, such as plaque-related inflammation and traumatic toothbrushing. Gingival recession is usually observed in the presence of trauma and inflammation in individuals with thin phenotypes, whereas pocket formation has been reported in individuals with thick phenotypes.
Soft tissue grafting in areas of thin phenotypes can enhance the quality of the gingival tissue. The best way to convert a thin soft tissue to a thick phenotype is through subepithelial connective tissue grafting Various other soft tissue augmentation procedures include: - modified roll technique and use of acellular dermal matrix. There were many drawback of these techniques such as were not cost effective, complications, second surgical site creation, healing and time consuming, etc.
Therefore marked transformation in the field of periodontics has led to the development of newer, less invasive therapeutic approaches, which allows proper management of surrounding tissues to provide best outcome of periodontal therapy. Minimally invasive treatment approaches help to achieve satisfactory therapeutic results with minimum trauma to tissues. Recent study has shown i-PRF (injectable Platelet Rich Fibrin) and Microneedling procedures to be effective in increasing gingival tissue thickness.
I-PRF prepared according to low-speed centrifugation concept can provide a significant advantage for the regeneration process, as it is rich in platelets, leucocytes and growth factors. I-PRF clots and forms a gel form after approximately 10-15 min and preserves its content in the tissue for sustained release. Recent studies have shown that in comparison to PRP and the blood clot even though there is slight or no increases in blood cell concentrations and growth factors; i- PRF was capable of inducing higher cell migration and mRNA expression of TGF- β, PDGF, osteocalcin and significant increase in type I collagen gene expression. It has been suggested that i- PRF provides a three- dimensional fibrin clot network embedding platelets, leucocytes, type I collagen, osteocalcin and growth factors acting as a dynamic gel with additional release of growth factors up to 10 days. Hence studies have documented that i-PRF results in increased gingival thickness.
Microneedling (MN) is also known as "percutaneous collagen induction therapy." Microinjuries created by MN result in minimal superficial bleedings and create a wound- healing cascade from which various growth factors, such as platelet-derived growth factors, transforming growth factors, connective tissue growth factor and fibroblast growth factors, are released. In MN, the tissue responds as if experiencing tissue trauma and the body's own collagen production is induced to preserve skin integrity. Study has shown a statistically significant increase in gingival thickness when microneedling was performed along with i- PRF in comparison to standalone i-PRF.
Only one study have evaluated effect of i-PRF alone and with microneedling on thin phenotype . To the best of our knowledge no studies have been conducted till now using microneedling alone to observe its effect on gingival thickness on thin periodontal phenotype. Considering the effects of MN and i-PRF on the biological potential, neoangiogenesis, neocollagenesis and wound, the present Randomized clinical trial is designed to compare and evaluate the effects of MN and i-PRF alone in thin periodontal phenotype. The null hypothesis is that there is no significant difference in the clinical outcome in microneedling and i-PRF on thin periodontal phenotype.
MATERIALS AND METHODOLOGY
SETTINGS: The present prospective, analytical, split mouth clinical trial will be conducted in the Department of Periodontics, Post Graduate Institute of Dental Sciences, Rohtak STUDY DESIGN: Interventional study. TIME FRAME: 12-14 months STUDY
Written and verbal consent will be taken from the willing participants. This Split mouth clinical trial will include 20 systemically healthy patients, with thin periodontal phenotype in mandibular anteriors.
Test group I : microneedling Test group II : i-PRF METHOD OF RECRUITMENT
In power analysis, it was found that a minimum of 18 cases will be required for each group at a 95% confidence level and 80% power when analysed with a mean difference of 0.5 mm and a standard deviation of 0.47 using the soft tissue thickness as a reference.
Estimating a 10% drop-out rate, the study includes 20 individuals with thin periodontal phenotypes who will consult to the Department of Periodontology, Post Graduate Institute of Dental Sciences, Rohtak .
BLINDING/MASKING Single blinding will be adopted where the investigator analysing the results will be unaware to which group the patient belongs.
PHASE I THERAPY All the participants will undergo phase-I therapy with a combination of hand scalers and curettes and ultrasonic scaler. Oral hygiene instructions will be imparted and will be reinforced at each appointment.
INTERVENTION Local anaesthesia will be administered. TEST GROUP I Thin periodontal phenotype will be treated with microneedling. A total of 4 sessions will be done with an interval of 10 days each. And all the parameters will be measured.
TEST GROUP II Thin periodontal phenotype will be treated with i-PRF procedure. A total of 4 sessions will be done with an interval of 10 days each. And all the parameters will be measured.
DATA COLLECTION METHODS To measure GT from the apical 1.5 mm of the gingival margin, a No:15 endodontic spreader with a 3-mm-diameter silicone disc will be placed in the centre and will be measured on Vernier caliper.
Keratinised tissue width will be measured with the help of UNC 15 probe with silicon disc stopper from the mucogingival junction to the free gingival margin and will be measured on Vernier caliper.
PPD will be measured using UNC 15 periodontal probe at six sites (mesiobuccal, distobuccal, mesiolingual , distolingual , and median points at buccal and lingual aspect).
GI, PI will be measured using UNC 15 periodontal probe at four sites (distofacial, mesiofacial, facial, lingual gingival margin).
All clinical parameters will be measured at baseline, 3 months and 6 months and 1 year.
DATA MANAGEMENT AND STATISTICAL ANALYSIS Data recorded will be processed by standard statistical analysis. The normality of distribution of data will be examined by Shapiro Wilk test. Statistical analysis will be performed according to distribution of data. If it is in normal distribution inter group comparison will be done by using Independent T test and paired t test will be use for intragroup comparison and if non-normal distributionof data, inter group comparison will be done by Mann-Whitney U test and intragroup by signed rank test. The Chi square test will be applied to analyze categoric data. Correlation and association between predictors and dependent variables will be analyzed by correlation analysis and regression analysis.
- Conditions
- Thin Gingiva
- Being tested
- Microneedling, injectable- platelet rich fibrin
- Keywords
- periodontal phenotype
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
MicroneedlingProcedure or surgery
MN will be carried out 1mm below of the gingival margin on the gingiva of the tooth to be treated with thirty-gauge (0.255 mm) lancet needles.
injectable- platelet rich fibrinProcedure or surgery
I-PRF will be prepared according to Choukroun PRF method.
| Study group | Role | What they receive |
|---|---|---|
| TEST GROUP I | Experimental | Thin periodontal phenotype will be treated with microneedling. A total of 4 sessions will be done with an interval of 10 days each. And all the parameters will be measured. Receives: Procedure: Microneedling |
| TEST GROUP II | Active comparator | Thin periodontal phenotype will be treated with i-PRF procedure. A total of 4 sessions will be done with an interval of 10 days each. And all the parameters will be measured. Receives: Procedure: injectable- platelet rich fibrin |
What is being measured
The primary outcome is the main question the study is designed to answer.
Gingival thickness (GT)
GT was determined at a mid-buccal location about 1mm apical to the Pocket Depth with a #15 endodontic reamer.
Measured: 6 months
Secondary outcomes (2)
Keratinized tissue width (KTW)
Keratinised tissue width will be measured with the help of UNC 15 probe with silicon disc stopper from the mucogingival junction to the free gingival margin.
Measured: 6 months
Pocket Probing Depth (PD)
PD will be measured using UNC 15 periodontal probe at six sites (mesiobuccal, distobuccal, mesiolingual , distolingual , and median points at buccal and lingual aspect).
Measured: 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Sep 2021
- Study startNov 2021 (estimated)
- Primary completionJul 2022 (estimated)
- Study completionSep 2022 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Thin GingivaStudies of the same condition, open and under way.
- More trials run by Postgraduate Institute of Dental Sciences RohtakThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Investigator
- Enrolment
- 20 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Postgraduate Institute of Dental Sciences Rohtak
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- ANJALI YADAV, Principal investigator, PGIDS,ROHTAK
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05055765
- Sponsor's protocol ID
- Anjali Yadav perio
- Status last verified
- Nov 2021
- First submitted
- 15 Sep 2021
- Last updated
- 17 Nov 2021
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 17 Nov 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Comparative Evaluation Of Microneedling vs Injectable Platelet Rich Fibrin In Thin Periodontal Phenotype: A Randomised Split Mouth Clinical Trial
- ClinicalTrials.gov ID
- NCT05055765
- Acronym / sponsor ID
- Anjali Yadav perio
- Conditions
- Thin Gingiva
- Keywords
- periodontal phenotype
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 20 participants (estimated)
- Lead sponsor
- Postgraduate Institute of Dental Sciences RohtakUniversity, hospital or other
- Study start
- Nov 2021 (estimated)
- Primary completion
- Jul 2022 (estimated)
- Study completion
- Sep 2022 (estimated)
- First posted
- 24 Sep 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Evaluation of microneedling vs injectable -platelet rich fibrin on gingival phenotype in thin periodontal phenotype.
Detailed description
INTRODUCTION The gingival phenotype and different parts of the masticatory mucosa have become the subject of considerable interest in Periodontics, especially from an aesthetic and therapeutic perspective. The periodontal phenotype has been defined as the combination of gingival phenotype and buccal bone plate thickness (bone morphotype). Gingival phenotype refers to gingival thickness (GT) and keratinized tissue width (KTW).
Gingival phenotypes can be classified as scalloped and thin or flat and thick gingiva. A gingival thickness of ≥1 mm is defined as thick phenotype and a gingival thickness of ≤1 mm as thin phenotype1. Thin gingival phenotype are very friable and might be prone to recede in response to traumatic insults, such as plaque-related inflammation and traumatic toothbrushing. Gingival recession is usually observed in the presence of trauma and inflammation in individuals with thin phenotypes, whereas pocket formation has been reported in individuals with thick phenotypes.
Soft tissue grafting in areas of thin phenotypes can enhance the quality of the gingival tissue. The best way to convert a thin soft tissue to a thick phenotype is through subepithelial connective tissue grafting Various other soft tissue augmentation procedures include: - modified roll technique and use of acellular dermal matrix. There were many drawback of these techniques such as were not cost effective, complications, second surgical site creation, healing and time consuming, etc.
Therefore marked transformation in the field of periodontics has led to the development of newer, less invasive therapeutic approaches, which allows proper management of surrounding tissues to provide best outcome of periodontal therapy. Minimally invasive treatment approaches help to achieve satisfactory therapeutic results with minimum trauma to tissues. Recent study has shown i-PRF (injectable Platelet Rich Fibrin) and Microneedling procedures to be effective in increasing gingival tissue thickness.
I-PRF prepared according to low-speed centrifugation concept can provide a significant advantage for the regeneration process, as it is rich in platelets, leucocytes and growth factors. I-PRF clots and forms a gel form after approximately 10-15 min and preserves its content in the tissue for sustained release. Recent studies have shown that in comparison to PRP and the blood clot even though there is slight or no increases in blood cell concentrations and growth factors; i- PRF was capable of inducing higher cell migration and mRNA expression of TGF- β, PDGF, osteocalcin and significant increase in type I collagen gene expression. It has been suggested that i- PRF provides a three- dimensional fibrin clot network embedding platelets, leucocytes, type I collagen, osteocalcin and growth factors acting as a dynamic gel with additional release of growth factors up to 10 days. Hence studies have documented that i-PRF results in increased gingival thickness.
Microneedling (MN) is also known as "percutaneous collagen induction therapy." Microinjuries created by MN result in minimal superficial bleedings and create a wound- healing cascade from which various growth factors, such as platelet-derived growth factors, transforming growth factors, connective tissue growth factor and fibroblast growth factors, are released. In MN, the tissue responds as if experiencing tissue trauma and the body's own collagen production is induced to preserve skin integrity. Study has shown a statistically significant increase in gingival thickness when microneedling was performed along with i- PRF in comparison to standalone i-PRF.
Only one study have evaluated effect of i-PRF alone and with microneedling on thin phenotype . To the best of our knowledge no studies have been conducted till now using microneedling alone to observe its effect on gingival thickness on thin periodontal phenotype. Considering the effects of MN and i-PRF on the biological potential, neoangiogenesis, neocollagenesis and wound, the present Randomized clinical trial is designed to compare and evaluate the effects of MN and i-PRF alone in thin periodontal phenotype. The null hypothesis is that there is no significant difference in the clinical outcome in microneedling and i-PRF on thin periodontal phenotype.
MATERIALS AND METHODOLOGY
SETTINGS: The present prospective, analytical, split mouth clinical trial will be conducted in the Department of Periodontics, Post Graduate Institute of Dental Sciences, Rohtak STUDY DESIGN: Interventional study. TIME FRAME: 12-14 months STUDY
Written and verbal consent will be taken from the willing participants. This Split mouth clinical trial will include 20 systemically healthy patients, with thin periodontal phenotype in mandibular anteriors.
Test group I : microneedling Test group II : i-PRF METHOD OF RECRUITMENT
In power analysis, it was found that a minimum of 18 cases will be required for each group at a 95% confidence level and 80% power when analysed with a mean difference of 0.5 mm and a standard deviation of 0.47 using the soft tissue thickness as a reference.
Estimating a 10% drop-out rate, the study includes 20 individuals with thin periodontal phenotypes who will consult to the Department of Periodontology, Post Graduate Institute of Dental Sciences, Rohtak .
BLINDING/MASKING Single blinding will be adopted where the investigator analysing the results will be unaware to which group the patient belongs.
PHASE I THERAPY All the participants will undergo phase-I therapy with a combination of hand scalers and curettes and ultrasonic scaler. Oral hygiene instructions will be imparted and will be reinforced at each appointment.
INTERVENTION Local anaesthesia will be administered. TEST GROUP I Thin periodontal phenotype will be treated with microneedling. A total of 4 sessions will be done with an interval of 10 days each. And all the parameters will be measured.
TEST GROUP II Thin periodontal phenotype will be treated with i-PRF procedure. A total of 4 sessions will be done with an interval of 10 days each. And all the parameters will be measured.
DATA COLLECTION METHODS To measure GT from the apical 1.5 mm of the gingival margin, a No:15 endodontic spreader with a 3-mm-diameter silicone disc will be placed in the centre and will be measured on Vernier caliper.
Keratinised tissue width will be measured with the help of UNC 15 probe with silicon disc stopper from the mucogingival junction to the free gingival margin and will be measured on Vernier caliper.
PPD will be measured using UNC 15 periodontal probe at six sites (mesiobuccal, distobuccal, mesiolingual , distolingual , and median points at buccal and lingual aspect).
GI, PI will be measured using UNC 15 periodontal probe at four sites (distofacial, mesiofacial, facial, lingual gingival margin).
All clinical parameters will be measured at baseline, 3 months and 6 months and 1 year.
DATA MANAGEMENT AND STATISTICAL ANALYSIS Data recorded will be processed by standard statistical analysis. The normality of distribution of data will be examined by Shapiro Wilk test. Statistical analysis will be performed according to distribution of data. If it is in normal distribution inter group comparison will be done by using Independent T test and paired t test will be use for intragroup comparison and if non-normal distributionof data, inter group comparison will be done by Mann-Whitney U test and intragroup by signed rank test. The Chi square test will be applied to analyze categoric data. Correlation and association between predictors and dependent variables will be analyzed by correlation analysis and regression analysis.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| TEST GROUP I | Experimental | Procedure: MicroneedlingThin periodontal phenotype will be treated with microneedling. A total of 4 sessions will be done with an interval of 10 days each. And all the parameters will be measured. |
| TEST GROUP II | Active comparator | Procedure: injectable- platelet rich fibrinThin periodontal phenotype will be treated with i-PRF procedure. A total of 4 sessions will be done with an interval of 10 days each. And all the parameters will be measured. |
Who may qualify
- Ages
- 18 to 40 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (3 listed)
- GT of the mandibular and maxillary anterior teeth < 1 mm, gingival index (GI) of < 1
- Age 18-40 years and otherwise systemically healthy
- Patients who had completed etiological periodontal therapy with Plaque index <1, gingival index <1 and showing adequate compliance and willing to participate in the study.
Key exclusion criteria (8 listed)
- Patients having systemic diseases such as hypertension, diabetes, hyperthyroidism or on medications that influence the outcome of periodontal procedure
- Pregnant and lactating women
- Smokers, tobacco users
- Previous periodontal surgery
- No haematological disorders
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| MicroneedlingMN will be carried out 1mm below of the gingival margin on the gingiva of the tooth to be treated with thirty-gauge (0.255 mm) lancet needles. | Procedure or surgery | TEST GROUP I |
| injectable- platelet rich fibrinI-PRF will be prepared according to Choukroun PRF method. | Procedure or surgery | TEST GROUP II |
Primary outcome
Gingival thickness (GT)
Time frame: 6 months
GT was determined at a mid-buccal location about 1mm apical to the Pocket Depth with a #15 endodontic reamer.
2 secondary outcomes
Keratinized tissue width (KTW)
Time frame: 6 months
Pocket Probing Depth (PD)
Time frame: 6 months
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Nov 2021.
Related trials for Thin Gingiva
Recruiting
Evaluation of Different Grafting Technique of Thin Gingival Phenotype With Delayed Dental Implants
Implant Dentistry, Connective Tissue Graft
Not yet recruiting
Injectable Platelet-Rich Fibrin and Microneedling With or Without Vitamin C for Gingival Phenotype Augmentation.
Thin Gingival Phenotype
Not yet recruiting
Dimensional Changes: Randomized Clinical Trial
Gingival Recession
Recruiting
Gain of Keratinized Mucosa Around Teeth and Dental Implants Using a Combination of Strip Gingival Graft and Acellular Dermal Matrix
Gingival Recession, Lack of Keratinized Attached Peri-implant Mucosa
Not yet recruiting
Super Putty C-PRF/ Hyaluronic Acid Combination vs C-PRF in Gingival Phenotype Modification in Subjects With Thin Gingival Phenotype
Thin Gingival Phenotype
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
NISHI TANWAR contact
ANJALI YADAV principal investigator
PGIDS,ROHTAK
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Microneedling and injectable- platelet rich fibrin in people with Thin Gingiva, run by Postgraduate Institute of Dental Sciences Rohtak at 1 site in India.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 17 Nov 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in India. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact SANJAY TEWARI (01262-283876, principalpgids@yahoo.in), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Gingival thickness (GT) (time frame: 6 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Nov 2021.